Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 23, 2026 08:05 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas

SANGAMO THERAPEUTICS ENTERS INTO ASSET SALE AGREEMENTS WITH LILLY AND ASTELLAS
June 08, 2026 08:05 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders

Sangamo Therapeutics announces exploration of strategic alternatives to maximize value for stakeholders
May 14, 2026 16:01 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

Sangamo Therapeutics reports first quarter 2026 business updates and financial results
May 11, 2026 16:05 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

SANGAMO THERAPEUTICS ANNOUNCES FIRST QUARTER 2026 EARNINGS CALL
April 30, 2026 08:05 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

SANGAMO THERAPEUTICS TO PRESENT PIPELINE AND TECHNOLOGY ADVANCES AT THE 29TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT)
April 29, 2026 08:05 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

Sangamo’s common stock to transition trading from The Nasdaq Capital Market to OTCQB Venture Market beginning May 5, 2026
March 30, 2026 16:01 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

Sangamo Therapeutics reports recent business highlights and fourth quarter and full year 2025 financial results
March 19, 2026 16:03 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

SANGAMO THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 EARNINGS CALL
March 09, 2026 08:05 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Sangamo has now submitted the ST-920 preclinical and clinical modules to the FDA for review.
February 03, 2026 16:05 ET | Source: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026

SANGAMO THERAPEUTICS PRESENTS DETAILED DATA FROM REGISTRATIONAL STAAR STUDY IN FABRY DISEASE AT WORLDSYMPOSIUM 2026